Samuel H. A. Andersson

Samuel H. A. Andersson

Auto-generated profile, based on publicly available information

Samuel H. A. Andersson

Department of Clinical Sciences, Malmö, Cardiovascular Research – Immune Regulation, Lund University, Malmö, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MMMegan Mulholland
Megan Mulholland
ACAnthi Chalou
Anthi Chalou
SASamuel H. A. Andersson
Samuel H. A. Andersson
MDMarie Depuydt
Marie Depuydt
YYYinda Yu
Yinda Yu
DEDaniel Engelbertsen
Daniel Engelbertsen
Immune checkpoint inhibitors (ICIs), targeting checkpoint receptors such as programmed cell death protein 1 (PD-1), are associated with increased risk of cardiovascular events, but the underlying mechanisms remain poorly understood. Here we show that PD-1+ T cells from murine atherosclerotic aortas mainly display a progenitor exhausted phenotype (PD-1intSlamf6+Tim3−), produce IFNγ in vivo, exhibit signs of recent proliferation and maintain polyfunctionality. PD-1 blockade induced marked changes in plaque immune phenotype, with increased PD-1high T cell accumulation, IFNγ production, formation of lymphocyte foci and neutrophil recruitment. Depletion of PD-1high T cells prior to PD-1 blockade did not impede T cell recruitment, suggesting a role for progenitor exhausted PD-1int T cells in ICI-driven T cell plaque accumulation. Human circulating PD-1+ T cells produced IFNγ and were associated with subclinical coronary atherosclerosis. Our studies highlight IFNγ-producing PD-1+ T cells as a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving ICI.